References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. doi: 10.3322/caac.21492
- Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 2019; 94: 1623–40. doi: 10.1016/j.mayocp.2019.01.013
- Brown S, Banfill K, Aznar MC, Whitehurst P, Faivre Finn C. The evolving role of radiotherapy in non-small cell lung cancer. Br J Radiol 2019; 92: 20190524. doi: 10.1259/bjr.20190524
- Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022; 40: 1301–11. doi: 10.1200/JCO.21.01308
- Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919–29. doi: 10.1056/NEJMoa1709937
- Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K, Saijo N. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 2001; 49: 649–55. doi: 10.1016/s0360-3016(00)00783-5
- Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, Muñoz-Montaño W, Nuñez-Baez M, Arrieta O. Radiation-induced lung injury: current evidence. BMC Pulm Med 2021; 21: 9. doi: 10.1186/s12890-020-01376-4
- Hagiwara Y, Nakayama Y, Kudo S, Hayakawa T, Nakamura N, Kitamoto Y, et al. Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease. J Radiat Res 2020; 61: 563–74. doi: 10.1093/jrr/rraa018
- Kashihara T, Nakayama Y, Ito K, Kubo Y, Okuma K, Shima S, et al. Usefulness of simple original interstitial lung abnormality scores for predicting radiation pneumonitis requiring steroidal treatment after definitive radiation therapy for patients with locally advanced non-small cell lung cancer. Adv Radiat Oncol 2021; 6: 100606. doi: 10.1016/j.adro.2020.10.019
- Higo H, Kubo T, Makimoto S, Makimoto G, Ihara H, Masaoka Y, et al. Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. Jpn J Clin Oncol 2019; 49: 458–64. doi: 10.1093/jjco/hyz016
- Washko GR, Lynch DA, Matsuoka S, Ross JC, Umeoka S, Diaz A, et al. Identification of early interstitial lung disease in smokers from the COPDGene Study. Acad Radiol 2010; 17: 48–53. doi: 10.1016/j.acra.2009.07.016
- Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med 2020; 8: 726–37. doi: 10.1016/S2213-2600(20)30168-5
- Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452–8. doi: 10.1038/bmt.2012.244
- Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 2007; 96: 644–7. doi: 10.1111/j.1651-2227.2006.00178.x
- Li F, Zhou Z, Wu A, Cai Y, Wu H, Chen M, et al. Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. Radiat Oncol 2018; 13: 82. doi: 10.1186/s13014-018-1030-1
- Kobayashi H, Wakuda K, Naito T, Mamesaya N, Omori S, Ono A, et al. Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities. Radiat Oncol 2021; 16: 52. doi: 10.1186/s13014-021-01780-y
- Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011; 364: 897–906. doi: 10.1056/NEJMoa1007285
- Chua F, Desai SR, Nicholson AG, Devaraj A, Renzoni E, Rice A, et al. Pleuroparenchymal fibroelastosis. A review of clinical, radiological, and pathological characteristics. Ann Am Thorac Soc 2019; 16: 1351–59. doi: 10.1513/AnnalsATS.201902-181CME
- Oshiro Y, Mizumoto M, Sekino Y, Maruo K, Ishida T, Sumiya T, et al. Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: multi-institutional research in Japan. Clin Transl Radiat Oncol 2021; 29: 54–59. doi: 10.1016/j.ctro.2021.05.009
- Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013; 85: 444–50. doi: 10.1016/j.ijrobp.2012.04.043
- Ito M, Shimizu H, Aoyama T, Tachibana H, Tomita N, Makita C, et al. Efficacy of virtual block objects in reducing the lung dose in helical tomotherapy planning for cervical oesophageal cancer: a planning study. Radiat Oncol 2018; 13: 62. doi: 10.1186/s13014-018-1012-3
- Wu WC, Chan CL, Wong YW, Cuijpers JP. A study on the influence of breathing phases in intensity-modulated radiotherapy of lung tumours using four-dimensional CT. Br J Radiol 2010; 83: 252–6. doi: 10.1259/bjr/33094251
- Putman RK, Gudmundsson G, Axelsson GT, Hida T, Honda O, Araki T, et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med 2019; 200: 175–83. doi: 10.1164/rccm.201809-1652OC
- Iwasawa T, Okudela K, Takemura T, Fukuda T, Matsushita S, Baba T, et al. Computer-aided quantification of pulmonary fibrosis in patients with lung cancer: Relationship to disease-free survival. Radiology 2019; 292: 489–98. doi: 10.1148/radiol.2019182466
- Araki T, Dahlberg SE, Hida T, Lydon CA, Rabin MS, Hatabu H, et al. Interstitial lung abnormality in stage IV non-small cell lung cancer: a validation study for the association with poor clinical outcome. Eur J Radiol Open 2019; 6: 128–31. doi: 10.1016/j.ejro.2019.03.003
- Kashihara T, Nakayama Y, Okuma K, Takahashi A, Kaneda T, Katagiri M, et al. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer. Radiother Oncol 2023; 180: 109454. doi: 10.1016/j.radonc.2022.109454